← Back to screener

Lineage Cell Therapeutics, Inc. LCTX

Rank #2219 · NYSE · $0.2B market cap
Audited by Baker Tilly US, LLP, no going-concern flag in the latest filing.
Score
28.9
P/E
-13.4
P/B
3.18
ROE
-23.7%
Op. Margin
-226.1%
Debt Ratio
46%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Weak

P/E -13.4x, P/B 3.18x. Ranks in the top 68% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -23.7%. Ranks in the top 88% of the universe.

Safety ★★★★☆
Good

Debt ratio 46%. Ranks in the top 22% of the universe. Under 100% is generally considered a safe level.

Growth ★★★☆☆
Average

Revenue growth of 6.2% year over year. Ranks in the top 45% of the universe.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011–$-0.0B$-0.0B$0.0B–40
2012$0.0B$-0.0B$-0.0B$0.0B-265.760
2013$0.0B$-0.0B$-0.0B$0.0B-421.4210
2014$0.0B$-0.0B$-0.0B$0.0B-638.5290
2015$0.0B$-0.1B$-0.0B$0.0B-1262.7105
2016–$-0.1B$-0.0B$0.0B–71
2017–$-0.1B$-0.0B$0.1B–10
2018$0.0B$-0.0B$-0.0B$0.2B-1125.06
2019$0.0B$-0.0B$-0.0B$0.1B-837.910
2020$0.0B$-0.0B$-0.0B$0.1B-1106.013
2021$0.0B$-0.0B$-0.0B$0.1B-1448.413
2022$0.0B$-0.0B$-0.0B$0.1B-1133.691
2023$0.0B$-0.0B$-0.0B$0.1B-153.271
2024$0.0B$-0.0B$-0.0B$0.1B-276.561
2025$0.0B$-0.0B$-0.0B$0.1B-226.146

← See the full screener